AIM-HI Accelerator Fund portfolio firm receives Virginia Catalyst funding

ROCKVILLE, MD – A portfolio start-up company of the AIM-HI Accelerator Fund has been awarded $700,000 from Virginia Catalyst to commercialize its lead cancer drug candidate. Richmond-based InterLeukin Combinatorial Therapies (ILCT) is developing unique engineered therapeutic interleukins (a type of protein) which destabilize and can kill cancer cells. The grant was one of six, totaling…

Novela Neurotech showcases smart neural interface at Creative Destruction Lab

TORONTO, ON – Novela Neurotech, a MedTech company developing AI-powered wireless, “smart” neural interface systems, joins Canada’s Creative Destruction Lab to further fine-tune its health technologies to the needs of patients with difficult neurological disorders. “Our core mission is to foster a new era of neurological treatments by focusing on their electrical signaling within the…

Direct-to-consumer fertility tests confuse and mislead consumers, Penn study shows

PHILADELPHIA – Direct-to-consumer hormone-based “fertility testing” for women is viewed by consumers as both an alternative, empowering tool for family planning, and a confusing and misleading one, according to the results of a new study from Penn Medicine. Findings from the small, first-of-its-kind ethnographic study reinforce the need for consumer education around the purpose and…